Stocktoria
Nurix Therapeutics, Inc. NRIX
Nurix Therapeutics, Inc. (NRIX) earns a Piotroski F-score of 3/9 (weak financial health), with an Altman Z″ in the grey zone. It does not currently pay a dividend. FY2025 revenue was $84.0M at a -314.9% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Analyst price target
Wall Street analyst consensus — a sentiment gauge, not our scoring.
Smart money · insiders, last 12 months
Open-market insider purchases minus sells (SEC Form 4) — real buying with their own money is a bullish “smart money” signal; grants and option exercises are excluded.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 3/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · grey zone
| Component | Value |
|---|---|
| Working capital / assets | 0.756 |
| Retained earnings / assets | -1.458 |
| EBIT / assets | -0.415 |
| Equity / liabilities | 3.606 |
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| NRIX | Nurix Therapeutics, Inc. | 3/9 | 1.2 | — | +54% |
| SPRY | ARS Pharmaceuticals, Inc. | 3/9 | -1.13 | — | -5.5% |
| ARCT | Arcturus Therapeutics Holdings Inc. | 1/9 | 0.81 | — | -46.1% |
| ETON | Eton Pharmaceuticals, Inc. | 5/9 | -2.05 | — | +104.9% |
| CYTK | CYTOKINETICS INC | 3/9 | -7.91 | — | +376.6% |
| CTMX | CytomX Therapeutics, Inc. | 1/9 | -10.12 | — | -44.8% |
| ABCL | AbCellera Biologics Inc. | 4/9 | 4.67 | — | +160.6% |
About Nurix Therapeutics, Inc.
Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and antibody therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-5948, an orally bioavailable BTK degrader, that is in Phase 2 clinical trials for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader, that is in Phase Phase 1a/1b clinical trials for the treatment of relapsed or refractory B-cell malignancies; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor, that is in Phase 1a/1b clinical trials to treat immuno-oncology indications. It is also developing NX-0479/GS-6791, a IRAK4 degrader for the treatment of rheumatoid arthritis and other inflammatory diseases. The company has a strategic collaboration agreement with Gilead Sciences, Inc. (Gilead), Sanofi S.A. (Sanofi), and Pfizer Inc. (Pfizer) for co-development and co-commercialization for multiple drug candidates. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. Nurix Therapeutics, Inc. was incorporated in 2009 and is headquartered in Brisbane, California.
FAQ
Is NRIX financially healthy?
Nurix Therapeutics, Inc.'s Piotroski F-score is 3/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the grey zone.
Does NRIX pay a dividend?
No, Nurix Therapeutics, Inc. does not currently pay a dividend.
How profitable is NRIX?
In FY2025, Nurix Therapeutics, Inc. had a net margin of -314.9% and a return on equity of -49.1%.
What is the analyst price target for NRIX?
The average Wall-Street price target for Nurix Therapeutics, Inc. is $31.44, about 18.1% above the recent price, from 16 analysts (consensus: strong buy).
Is NRIX a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on Nurix Therapeutics, Inc.: a Piotroski F-score of 3/9, an Altman Z″ in the grey zone. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-11-30. Facts plus Stocktoria's own computed scores — not investment advice.